Healthcare of Ontario Pension Plan Trust Fund Has $1.69 Million Stock Holdings in Biogen Inc. $BIIB

Healthcare of Ontario Pension Plan Trust Fund decreased its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 78.4% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 9,220 shares of the biotechnology company’s stock after selling 33,522 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Biogen were worth $1,690,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of Biogen by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 17,447,092 shares of the biotechnology company’s stock valued at $3,070,514,000 after buying an additional 157,857 shares in the last quarter. Geode Capital Management LLC raised its position in Biogen by 3.2% during the fourth quarter. Geode Capital Management LLC now owns 4,199,399 shares of the biotechnology company’s stock worth $736,435,000 after acquiring an additional 130,618 shares in the last quarter. Norges Bank bought a new stake in Biogen during the fourth quarter worth $464,408,000. Invesco Ltd. lifted its stake in Biogen by 4.2% in the third quarter. Invesco Ltd. now owns 2,418,127 shares of the biotechnology company’s stock valued at $338,731,000 after acquiring an additional 98,001 shares during the last quarter. Finally, Morgan Stanley lifted its stake in Biogen by 3.3% in the fourth quarter. Morgan Stanley now owns 2,325,013 shares of the biotechnology company’s stock valued at $409,180,000 after acquiring an additional 73,478 shares during the last quarter. Institutional investors own 87.93% of the company’s stock.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen reported second-quarter revenue of $2.74 billion, up 3.4% year over year and ahead of consensus estimates of approximately $2.46 billion. Growth was led by newer products and the company’s growth portfolio, helping adjusted EPS reach $3.60 versus the $2.94 analyst estimate. Biogen beats quarterly estimates as newer drugs drive growth
• Positive Sentiment: Management raised its revenue outlook and highlighted continued momentum in newer medicines and strategic acquisitions, supporting the view that Biogen is gradually reducing its reliance on older products. Biogen raises revenue outlook as growth portfolio drives Q2 beat
• Positive Sentiment: Several analysts became more constructive after the results. TD Cowen raised its price target to $225 and upgraded the stock to Buy, while Morgan Stanley increased its target to $231, although it retained an Equal Weight rating. Barclays also expects the shares to rise.
• Neutral Sentiment: Wedbush raised its price target from $201 to $215 but maintained a Neutral rating, and Piper Sandler reaffirmed its Buy rating. Zacks upgraded Biogen from Strong Sell to Hold, indicating improving sentiment but not broad analyst conviction.
• Negative Sentiment: Reported profitability deteriorated substantially. Second-quarter net income fell to $97.5 million, while diluted EPS from continuing operations declined to $0.66 from $4.33 a year earlier; first-half net income also dropped to $417 million from $875.3 million. The sharp gap between revenue growth and reported earnings is raising concerns that profitability may be peaking. Biogen earnings and profitability analysis

Biogen Stock Performance

NASDAQ BIIB opened at $202.95 on Friday. The firm has a 50-day moving average of $201.23 and a 200-day moving average of $190.60. The company has a debt-to-equity ratio of 0.39, a quick ratio of 2.41 and a current ratio of 1.87. The stock has a market cap of $29.99 billion, a PE ratio of 35.92, a P/E/G ratio of 6.28 and a beta of 0.16. Biogen Inc. has a 52-week low of $124.56 and a 52-week high of $219.72.

Biogen (NASDAQ:BIIB) last announced its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, topping the consensus estimate of $2.94 by $0.66. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The business had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. During the same quarter in the previous year, the firm posted $5.47 EPS. Biogen’s revenue was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, sell-side analysts anticipate that Biogen Inc. will post 12.65 EPS for the current year.

Analysts Set New Price Targets

BIIB has been the topic of several recent analyst reports. JPMorgan Chase & Co. boosted their price objective on shares of Biogen from $175.00 to $185.00 and gave the stock a “neutral” rating in a research note on Thursday, April 23rd. UBS Group raised their target price on shares of Biogen from $225.00 to $240.00 and gave the company a “buy” rating in a research note on Thursday. Morgan Stanley lifted their price target on Biogen from $222.00 to $231.00 and gave the stock an “equal weight” rating in a report on Thursday. Barclays boosted their price target on Biogen from $185.00 to $200.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Finally, Evercore started coverage on Biogen in a research note on Friday, May 15th. They issued an “outperform” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $223.36.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.